Keyphrases
Previously Treated
100%
Immune Checkpoint Inhibitors
100%
Atezolizumab
100%
Stage IV Non-small Cell Lung Cancer
100%
Ramucirumab
100%
Overall Response Rate
50%
Clinical Benefit Rate
50%
Tumor Progression
33%
Treatment Options
16%
Hypertension
16%
Adverse Events
16%
Nausea
16%
Overall Survival
16%
Median Overall Survival
16%
Median Progression-free Survival
16%
Single Institution
16%
Phase II Study
16%
Growth Hormone Receptor
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
16%
Am(III)
16%
Complete Response
16%
Proteinuria
16%
Previously Untreated Patients
16%
Vascular Endothelial Growth Factor Receptor (VEGFR)
16%
Stable Disease
16%
Heavily Pretreated Patients
16%
Tolerability
16%
Systemic Treatment
16%
Platinum-based Chemotherapy
16%
RECIST 1.1
16%
Patients with Hypertension
16%
Nonsquamous Histology
16%
Treatment Line
16%
Overall Survival Progression-free Survival
16%
Vascular Endothelial Growth
16%
VEGF Inhibition
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Atezolizumab
100%
Ramucirumab
100%
Overall Survival
50%
Tumor Growth
33%
Progression Free Survival
33%
Receptor
16%
Nausea
16%
Adverse Event
16%
Chemotherapy
16%
Vasculotropin
16%
Tolerability
16%
Systemic Treatment
16%
Proteinuria
16%
Diseases
16%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Atezolizumab
100%
Ramucirumab
100%
Overall Survival
50%
Progression Free Survival
33%
Tumor Progression
33%
Nausea
16%
Adverse Event
16%
Receptor
16%
Proteinuria
16%
Systemic Therapy
16%
Vasculotropin
16%
Patient with Hypertension
16%
Diseases
16%